Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers

Ann Med. 2008;40(4):296-302. doi: 10.1080/07853890701832211.

Abstract

Background: Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease. Although supported by several large controlled trials, aspirin prevents only a portion of recurrent events.

Aim and method: We set out to study the prevalence of long-term aspirin use prior to admission for MI and its significance for medium-term event-free survival; 998 consecutive patients with acute MI admitted to a tertiary center were included in the study.

Results: Nearly half (42.4%) of all patients reported long-term use of low-dose aspirin prior to the index event. Prior aspirin use was associated with a 50% increase in the risk of both the combined end point of recurrent unstable angina, recurrent myocardial infarction, stroke, or death (OR 1.49; 95% CI 1.12-2.00, P=0.006) and mortality (OR 1.50; 95% CI 1.03-2.17, P=0.03) during 10-month follow-up. Prior aspirin use was not associated with an increased frequency of added antithrombotic therapy at discharge.

Conclusions: We have found that prior aspirin use is common in patients hospitalized for acute MI. Individuals already on aspirin had increased risk of recurrent ischemic events and all-cause mortality during the 10-month follow-up after their index MI.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angina, Unstable / epidemiology
  • Angina, Unstable / etiology
  • Aspirin / adverse effects
  • Aspirin / therapeutic use*
  • Coronary Disease / complications
  • Coronary Disease / mortality
  • Disease-Free Survival
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / etiology
  • Myocardial Infarction / mortality
  • Myocardial Infarction / prevention & control*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prevalence
  • Prospective Studies
  • Recurrence
  • Stroke / epidemiology
  • Stroke / etiology

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Aspirin